Is compounded semaglutide FDA approved?
No. Compounded semaglutide is not FDA approved. FDA approval applies to specific products — for semaglutide, the approved products are Wegovy, Ozempic, and Rybelsus — after review of manufacturing, safety, and effectiveness data. Compounded semaglutide is prepared by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under compounding law, and FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed. A compounded product is also not a "generic" of any approved product.
What compounded semaglutide legally is
Compounding is the pharmacy practice of preparing a medication for a patient under a prescription. With the semaglutide shortage resolved, mass-marketed compounded copies of approved products face significant federal restrictions, and compounded access generally depends on a prescriber documenting a patient-specific clinical need. Whether a particular prescription meets that standard is a case-specific medical and legal question this publication cannot decide.
What approval status means for evidence
The clinical trials behind Wegovy, Ozempic, and Rybelsus studied those specific approved formulations. Their results do not automatically establish the potency, absorption, effectiveness, or safety of any compounded semaglutide product — and evidence for injectable products never transfers to oral, ODT, sublingual, or troche formulations. See the safety guide for 503A vs 503B and the verification workflow before buying from any provider.